MedPath

177Lu-FAP-2286

Generic Name
177Lu-FAP-2286

A Study of 177Lu-FAP-2286 in Advanced Solid Tumors (LuMIERE)

Phase 1
Recruiting
Conditions
Solid Tumor
Interventions
First Posted Date
2021-06-25
Last Posted Date
2025-05-02
Lead Sponsor
Novartis Pharmaceuticals
Target Recruit Count
222
Registration Number
NCT04939610
Locations
🇺🇸

Hoag Hospital Irvine, Irvine, California, United States

🇺🇸

UAB Comprehensive Cancer Center, Birmingham, Alabama, United States

🇺🇸

UCSF Medical Center, San Francisco, California, United States

and more 6 locations
© Copyright 2025. All Rights Reserved by MedPath